Friday, October 01, 2021 12:52:51 PM
THE JAB SCAM IS FADING AWAY..... JAB STOCKS GETTING CRUSHED!!!!!!
Recent JNJ News
- Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation • PR Newswire (US) • 05/14/2026 08:01:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/13/2026 08:29:44 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter • Business Wire • 05/12/2026 11:45:00 AM
- Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference • Business Wire • 05/11/2026 08:34:00 PM
- Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP • PR Newswire (US) • 05/11/2026 12:00:00 PM
- Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission • PR Newswire (US) • 05/07/2026 12:00:00 PM
- Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease • PR Newswire (US) • 05/05/2026 12:05:00 PM
- Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease • PR Newswire (US) • 05/05/2026 12:05:00 PM
- Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System • Business Wire • 05/05/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:58:59 PM
- CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations • Business Wire • 04/30/2026 12:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:23:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:21:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:17:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:13:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:12:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:06:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 09:48:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 09:38:22 PM
- Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference • Business Wire • 04/27/2026 08:33:00 PM
